Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and 31P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P. Craven, Miroslawa Gorecka, David A. Broadbent, Peter Swoboda, Klaus K. Witte, Richard M. Cubbon, Hui Xue, Peter Kellman, John P. Greenwood, Sven Plein, Eylem Levelt
Format: Artigo
Idioma:anglès
Publicat: 2021
Accés en línia:https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Internet

https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf

Ítems similars